DSIJ Mindshare

52-week high alert: Pharma stock hit upper circuit as it announces outstanding results; India's leading fund buys stake in it!

The stock has impressive ROCE of 172 per cent and ROE of 129 per cent  

Vaishnavi Chauhan 0 6878 Article rating: 4.2

The operating profit witnessed a significant increase of 145.11 per cent on YoY basis, amounting to Rs 10.54 crore. Furthermore, company’s net profit showed a massive jump of 147.81 per cent from FY22, reaching Rs 8.50 crore.  

  

This mid-cap multibagger company invests in cell and gene therapy company ImmunoACT!

Through this collaboration, the company aims to bring CAR-T therapy to Indian patients at an affordable price, filling the gap in access to this novel treatment option.

Siddharth Mane 0 9690 Article rating: 3.3

CAR-T therapy has shown significant success in the western world as a promising treatment option. However, this innovative technology is currently unavailable in India. Through this collaboration, the company aims to bring CAR-T therapy to Indian patients at an affordable price, filling the gap in access to this novel treatment option. 

Multibagger from its 52-week low: This small-cap company announces stellar results with a 72 per cent jump in revenue in FY23!

The stock gave multibagger returns of 207.36 per cent from its 52-week low of Rs 13.32 per share.

Kiran Shroff 0 7567 Article rating: 3.8

The Group has announced the bonus share in the ratio of 4:1, which has been approved by the shareholders through a postal ballot on December 23, 2022, and the corresponding allotment of the same was successfully done on January 07, 2023. Previously, it announced a stock split from Rs 5 to Rs 1 and the same was successfully done on August 08, 2022.

RSS
First18541855185618571859186118621863Last
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR